Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
NKTR Hot Sheet
Rating Summary:3 Buy, 0 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Morgan Joseph reiterates a 'Buy' on Nektar Therapeutics (Nasdaq: NKTR), price target $12.
Morgan analyst says, "While Nektar Therapeutics continues to be stigmatized by the failure of its inhaled insulin program a few years ago, its PEG technology and pipeline are orchestrating a strong comeback, in our opinion. Since Howard Robin joined Nektar in 2007, the company has gone through a substantial transformation and is focused on monetizing its superior PEG technology platform. The recently announced lucrative partnership with AstraZeneca could be a harbinger of future deals for Nektar's pipeline drugs. NKTR-102, a pegylated version of irinotecan, is currently in mid-stage trials, and could be the company's next partnership candidate."
To see more analyst ratings on NKTR Click Here.
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.
Morgan analyst says, "While Nektar Therapeutics continues to be stigmatized by the failure of its inhaled insulin program a few years ago, its PEG technology and pipeline are orchestrating a strong comeback, in our opinion. Since Howard Robin joined Nektar in 2007, the company has gone through a substantial transformation and is focused on monetizing its superior PEG technology platform. The recently announced lucrative partnership with AstraZeneca could be a harbinger of future deals for Nektar's pipeline drugs. NKTR-102, a pegylated version of irinotecan, is currently in mid-stage trials, and could be the company's next partnership candidate."
To see more analyst ratings on NKTR Click Here.
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.
You May Also Be Interested In
- Canaccord Genuity Maintains a 'Hold' on Tiffany & Co. (TIF); Cutting PT and Estimates
- Goldman Sachs Boosts Numbers on PVH Corp (PVH) After Q1 Beat
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Morgan JosephSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
